This page shows the latest opicapone news and features for those working in and with pharma, biotech and healthcare.
The company fleshed out its movement disorder pipeline earlier this year by licensing opicapone from Portuguese drug maker BIAL.
Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adults with Parkinson's and end-of-dose motor fluctuations who cannot ... Opicapone is a third-generation
Opicapone (Bial) is a COMT inhibitor in phase III development in various European countries for the treatment of idiopathic Parkinson's. ... Bial plans to develop opicapone to be administered in combination with levodopa/carbidopa or
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...